- Investors pile into Sage Therapeutics (NASDAQ:SAGE) +65%) today. Shares are up $11.74 from the offer price of $18.00 on turnover of 2.6M.
- The clinical-stage biotech focuses on rare disorders of the central nervous system (CNS). Its lead product is SAGE-547 for the treatment of super-refractory status epilepticus (SE), a medical emergency where the patient has a seizure lasting longer than five minutes. It is associated with a high incidence of morbidity and mortality. There are ~150,000 cases of SE in the U.S. each year resulting in 30,000 deaths. SAGE-547 is currently in Phase 1/2 development.
- The IPO fills the company's coffers by ~$90M, increasing its cash position to ~$137M on a pro forma basis. It burned $17.5M in operations in 2013.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Benzinga.com (Jan 12, 2015)
at Benzinga.com (Dec 30, 2014)
at MarketWatch.com (Oct 3, 2014)
at MarketWatch.com (Jul 18, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs